Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Net Margin (2017 - 2025)

Historic Net Margin for Integra Lifesciences Holdings (IART) over the last 16 years, with Q3 2025 value amounting to 1.34%.

  • Integra Lifesciences Holdings' Net Margin rose 14600.0% to 1.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.15%, marking a year-over-year decrease of 297300.0%. This contributed to the annual value of 0.43% for FY2024, which is 48300.0% down from last year.
  • As of Q3 2025, Integra Lifesciences Holdings' Net Margin stood at 1.34%, which was up 14600.0% from 116.47% recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' Net Margin ranged from a high of 13.3% in Q4 2022 and a low of 116.47% during Q2 2025
  • Moreover, its 5-year median value for Net Margin was 5.1% (2023), whereas its average is 1.0%.
  • Per our database at Business Quant, Integra Lifesciences Holdings' Net Margin surged by 100200bps in 2021 and then crashed by -1135100bps in 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Net Margin (Quarter) stood at 11.19% in 2021, then increased by 19bps to 13.3% in 2022, then tumbled by -62bps to 5.0% in 2023, then fell by -12bps to 4.39% in 2024, then tumbled by -131bps to 1.34% in 2025.
  • Its last three reported values are 1.34% in Q3 2025, 116.47% for Q2 2025, and 6.61% during Q1 2025.